Evidence map›Paper›PMID 39083560›Full record

ArticlePLoS pathogens2024

Epstein-Barr virus protein EBNA-LP engages YY1 through leucine-rich motifs to promote naïve B cell transformation.

Jana M Cable, Nicolás M Reinoso-Vizcaino, Robert E White, Micah A Luftig

Abstract read
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Chromatin Control of EBV Infection and Latency.Current topics in microbiology and immunology · 2025
    Article
  4. Review
  5. Sp140L functions as a herpesvirus restriction factor suppressing viral transcription and activating interferon-stimulated genes.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  6. Article
  7. Multiple sclerosis and infection: history, EBV, and the search for mechanism.Microbiology and molecular biology reviews : MMBR · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Jana M CableDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America.
Nicolás M Reinoso-VizcainoDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America.
Robert E WhiteSection of Virology, Department of Infectious Disease, Imperial College London, London, United Kingdom.
Micah A LuftigDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America.ORCID 0000-0002-2964-1907

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI Laura Fish · 1985 to 2026
$174.8M
Viral Oncology Training GrantT32CA009111 · NCI · DUKE UNIVERSITY · PI LUFTIG, MICAH A. · 1985 to 2023
$8.9M
Host pathways regulating Epstein-Barr virus-mediated B cell growth transformationR01CA140337 · NCI · DUKE UNIVERSITY · PI LUFTIG, MICAH ALAN · 2011 to 2025
$5.9M
Metabolic regulation of Epstein-Barr Virus-infected tonsillar B cells by EBNA-LPF31DE031509 · NIDCR · DUKE UNIVERSITY · PI CABLE, JANA · 2022 to 2024
$118k
Medical Research Council MR/L008432/1NCI NIH HHS P30 CA014236NCI NIH HHS R01 CA140337NCI NIH HHS T32 CA009111NIDCR NIH HHS F31 DE031509
6 · The paper itself

Abstract

Epstein-Barr Virus (EBV) is associated with numerous cancers including B cell lymphomas. In vitro, EBV transforms primary B cells into immortalized Lymphoblastoid Cell Lines (LCLs) which serves as a model to study the role of viral proteins in EBV malignancies. EBV induced cellular transformation is driven by viral proteins including EBV-Nuclear Antigens (EBNAs). EBNA-LP is important for the transformation of naïve but not memory B cells. While EBNA-LP was thought to promote gene activation by EBNA2, EBNA-LP Knockout (LPKO) virus-infected cells express EBNA2-activated cellular genes efficiently. Therefore, a gap in knowledge exists as to what roles EBNA-LP plays in naïve B cell transformation. We developed a trans-complementation assay wherein transfection with wild-type EBNA-LP rescues the transformation of peripheral blood- and cord blood-derived naïve B cells by LPKO virus. Despite EBNA-LP phosphorylation sites being important in EBNA2 co-activation; neither phospho-mutant nor phospho-mimetic EBNA-LP was defective in rescuing naïve B cell outgrowth. However, we identified conserved leucine-rich motifs in EBNA-LP that were required for transformation of adult naïve and cord blood B cells. Because cellular PPAR-g coactivator (PGC) proteins use leucine-rich motifs to engage transcription factors including YY1, a key regulator of DNA looping and metabolism, we examined the role of EBNA-LP in engaging transcription factors. We found a significant overlap between EBNA-LP and YY1 in ChIP-Seq data. By Cut&Run, YY1 peaks unique to WT compared to LPKO LCLs occur at more highly expressed genes. Moreover, Cas9 knockout of YY1 in primary B cells prior to EBV infection indicated YY1 to be important for EBV-mediated transformation. We confirmed EBNA-LP and YY1 biochemical association in LCLs by endogenous co-immunoprecipitation and found that the EBNA-LP leucine-rich motifs were required for YY1 interaction in LCLs. We propose that EBNA-LP engages YY1 through conserved leucine-rich motifs to promote EBV transformation of naïve B cells.

Indexed as

B-LymphocytesCell Transformation, ViralHerpesvirus 4, HumanViral ProteinsYY1 Transcription FactorAmino Acid MotifsEpstein-Barr Virus InfectionsEpstein-Barr Virus Nuclear AntigensHumansLeucineEBNA-LP protein, Human herpesvirus 4Epstein-Barr Virus Nuclear AntigensLeucineViral ProteinsYY1 protein, humanYY1 Transcription Factor

Identifiers

PMID39083560
PMCPMC11318927

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.